Investor info

In December 2018, STALICLA closed its series A financing for a global amount of CHF 10million (CHF 1=$1) committed from high-profile biotech investors at a CHF 30 million pre-money valuation. Funds will be used to bring STP1 into clinical stage and invested in reinforcing STALICLA’s Databased Endophenotyping Patient Identification AI discovery platform. A second additional tranche of financing is expected in Q2 2019.

Market potential and financials

  • In addition to the major toll ASD takes on the quality of life of patients and their families, it ranks among the highest costing diseases to healthcare and education systems. A 2015 study conducted by the UC-Davis Center for Healthcare Policy and Research pegged ASD’s economic costs for 2015 at $268 billion in the United States. These figures are similar to recent estimates for diabetes and attention deficit and hyperactivity disorder (ADHD) and exceed the costs of stroke and hypertension. Currently the only evidence-based treatment for ASD is behavioral intervention, which is associated with a yearly cost-per-patient ranging between $60,000 and $130,000.
  • Initial target markets for STP1 are the US followed by the EU. Based on a conservative estimate of 1 in 110 for ASD prevalence (only including moderate to severe patients), the Phenotype 1 sub-population includes 20% of ASD patients or 1.2 million patients in the US and EU.
  • First revenues are expected in 2025, after clinical trials for STP1 are completed and market authorization is granted. STP1’s target annual revenues after a ramp-up phase can be estimated to c. $1-3 billion/year.

Regulatory incentive

Regulatory authorities have developed favorable frameworks and treatment development programs for unmet medical needs including the FDA’s Breakthrough therapy designation program.

Drug combination and repurposing

Drug repurposing mitigates development risks through better defined safety profiles and reduced cost and time to market. Repurposed drugs can also benefit from very strong patent protection in the context of new indications, dosages or combinatory formulas.


Latest News

Entrepreneur stories : Lynn-Allison Durham - Le bigdata pour soigner l’autisme

Read more

Search for content on Stalicla...